This week, scientists inject a CRISPR-based treatment into a human eye, a novel contact lens shows promise for red-green color blindness and a biologic eye drop for ocular graft-versus-host disease snags orphan drug status.

This learning plan, based on IRIS Registry measure IRIS44: Visual Field Progression in Glaucoma, reviews tools to assess the risk of glaucoma progression and the factors to consider when deciding stepwise treatment.

These 2 calculators estimate the 5-year risk that an person with ocular hypertension will develop primary open-angle glaucoma.

Investigators assessed the safety and efficacy of Schlemm canal stenting in combination with cataract surgery in eyes with mild to moderate primary open-angle glaucoma (POAG).

This cross-sectional study examined the association between genetic risk variants of primary open-angle glaucoma (POAG) and age at the time of diagnosis.

In this 1-Minute Video, Dr. Matthew Emanuel offers tips for diagnosing and managing a form of secondary open-angle glaucoma known as pseudoexfoliation syndrome, or pseudoexfoliation glaucoma.

In this webinar, Drs. Patel, Camejo, Blieden, Shen, and Reznik provide the comprehensive ophthalmologist with an overview of some of the major advances in the diagnosis and management of glaucoma.

Weekly case challenge

This randomized controlled trial compared selective laser trabeculoplasty (SLT) vs. topical glaucoma medication as a first-line treatment for open-angle glaucoma and ocular hypertension.